ArticleTropical medicine & international health : TM & IH2025
Diagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul.
Article in Tropical medicine & international health : TM & IH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of a Novel Peptide-Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection.Clinical and translational science · 2026Article
- Diagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul.Tropical medicine & international health : TM & IH · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundChagas disease, caused by Trypanosoma cruzi, remains a significant public health challenge in Latin America, with diagnostic limitations hindering control efforts.
aimOur study aimed to assess the diagnostic performance of four chimeric recombinant T. cruzi antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3 and IBMP-8.4) in a highly endemic region in southern Brazil.
methodsSerum samples from 333 individuals residing in Canguçu, Rio Grande do Sul, were tested using an in-house ELISA platform. We assessed the sensitivity, specificity, accuracy, and diagnostic odds ratio (DOR) of individual and combined IBMP antigens through serial and parallel testing strategies.
resultsAll antigens exhibited 100% specificity and high accuracy (≥ 93.4%), with IBMP-8.1 and IBMP-8.4 showing the best overall performance (sensitivities of 80.0% and 76.7%; DORs of 109,136 and 89,659, respectively). Parallel testing using the combinations IBMP-8.1 + IBMP-8.3 and IBMP-8.1 + IBMP-8.4 achieved ≥ 95% sensitivity and > 99% accuracy.
conclusionsThese findings support the use of IBMP chimeric antigens, particularly in combination, as reliable tools for Chagas disease diagnosis and surveillance, and highlight the importance of region-specific validation to ensure diagnostic equity in diverse endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.